SCHEMBL22493460

SCHEMBL22493460

Cc1ncccc1C(O)CNC(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 5/20 0.56
ADRB2 P07550 4/20 0.56
CYP2D6 P10635 4/20 0.56
ADRB1 P08588 2/20 0.56
NFKB1 P19838 2/20 0.56
BLM P54132 2/20 0.55
LMNA P02545 3/20 0.41
CASP7 P55210 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
KDM4E B2RXH2 1/20 0.40
CASP1 P29466 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22481180 1.00 HIF1A (0.56) HIF1AADRB2CYP2D6ADRB1NFKB1
SCHEMBL22480735 1.00 HIF1A (0.56) HIF1AADRB2CYP2D6ADRB1NFKB1
SCHEMBL22480930 0.84 ADRB1 (0.39) HIF1AADRB2CYP2D6ADRB1NFKB1
SCHEMBL22480736 0.83 HIF1A (0.55) HIF1AADRB2CYP2D6ADRB1NFKB1
SCHEMBL22481235 0.83 HIF1A (0.55) HIF1AADRB2CYP2D6ADRB1NFKB1
SCHEMBL22481143 0.83 ADRB2 (0.63) HIF1AADRB2CYP2D6ADRB1NFKB1
SCHEMBL10586982 0.83 ADRB2 (0.55) HIF1AADRB2CYP2D6ADRB1NFKB1
SCHEMBL22481136 0.82 ADRB2 (0.54) HIF1AADRB2CYP2D6ADRB1NFKB1
SCHEMBL24630971 0.81 HIF1A (0.52) HIF1AADRB2CYP2D6ADRB1NFKB1
SCHEMBL22864231 0.81 HIF1A (0.52) HIF1AADRB2CYP2D6ADRB1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137506-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
WO-2023225021-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) CURASEN THERAPEUTICS, INC. (US) 2023-11-23 WO disclosed
US-20230263749-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. 2023-08-24 US disclosed
US-20230157974-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. 2023-05-25 US disclosed
WO-2020198466-A9 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
WO-2020198466-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263749-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS ADRA2A, SNCA, ADRA1A HIF1A 701/4885ADRB2 4/4885CYP2D6 3407/4885
US-20230157974-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS ADRA2A, SNCA, ADRA1A HIF1A 701/4885ADRB2 4/4885CYP2D6 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.